TITLE

Single-Tablet Emtricitabine-Rilpivirine- Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men

AUTHOR(S)
Foster, Rosalind; McAllister, John; Read, Tim R.; Pierce, Anna B.; Richardson, Robyn; McNulty, Anna; Carr, Andrew
PUB. DATE
October 2015
SOURCE
Clinical Infectious Diseases;10/15/2015, Vol. 61 Issue 8, p1336
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Completion rates for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) are low. We investigated the adherence and safety of coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet regimen for PEP in men who have sex with men (MSM). Methods: In an open-label, single-arm study at 2 public sexual health clinics and 2 hospital emergency departments in urban Australia, 100 HIV-uninfected MSM requiring 3-drug PEP received single-tablet FTC-RPV-TDF once daily for 28 days. The primary endpoint was premature PEP cessation or primary HIV infection through week 12. Additional endpoints were adherence (by self-report of doses missed or not ingested with a meal, by pill count, and by plasma concentrations of tenofovir and FTC at week 4); and safety (clinical and laboratory adverse events [AEs]). Results: PEP completion was 92% (95% confidence interval, 85%-96%); premature cessation resulted from loss to follow-up (6%), AEs (1%), or study burden (1%). No participant was found to acquire HIV through week 12. Adherence was 98.6% (standard deviation [SD], 2.4) by pill count and 98.5% (SD, 2.7) by self-report; 86% reported taking all doses with food, and 88% of the subset tested had plasma tenofovir levels suggesting full adherence (>40 ng/mL). Eighty-eight participants experienced at least 1 clinical AE; 4 had grade 3 AEs or higher, possibly attributable to study drug. Fifty-six participants experienced at least 1 laboratory AE; 4 had AEs of grade 3 or higher, possibly attributable to study drug. Conclusions: A single-tablet regimen of FTC-RPV-TDF was well tolerated as once-daily PEP, with high levels of adherence and completion.
ACCESSION #
110259896

 

Related Articles

  • Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study. Porter, Danielle P.; Toma, Jonathan; Tan, Yuping; Solberg, Owen; Cai, Suqin; Kulkarni, Rima; Andreatta, Kristen; Lie, Yolanda; Chuck, Susan K.; Palella, Frank; Miller, Michael D.; White, Kirsten L. // HIV Clinical Trials;Jan2016, Vol. 17 Issue 1, p29 

    Objectives: Antiretroviral regimen switching may be considered for HIV-1-infected, virologically-suppressed patients to enable treatment simplification or improve tolerability, but should be guided by knowledge of pre-existing drug resistance. The current study examined the impact of...

  • No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Volk, Jonathan E.; Marcus, Julia L.; Phengrasamy, Tony; Blechinger, Derek; Nguyen, Dong Phuong; Follansbee, Stephen; Hare, C. Bradley // Clinical Infectious Diseases;11/15/2015, Vol. 61 Issue 10, p1601 

    Referrals for and initiation of preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection increased dramatically in a large clinical practice setting since 2012. Despite high rates of sexually transmitted infections among PrEP users and reported decreases in condom use in a...

  • No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. Marcus, Julia L.; Glidden, David V.; Mayer, Kenneth H.; Liu, Albert Y.; Buchbinder, Susan P.; Amico, K. Rivet; McMahan, Vanessa; Kallas, Esper Georges; Montoya-Herrera, Orlando; Pilotto, Jose; Grant, Robert M. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Objective: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We...

  • Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Havens, Peter L.; Stephensen, Charles B.; Van Loan, Marta D.; Schuster, Gertrud U.; Woodhouse, Leslie R.; Flynn, Patricia M.; Gordon, Catherine M.; Pan, Cynthia G.; Rutledge, Brandy; Nancy Liu; Wilson, Craig M.; Hazra, Rohan; Hosek, Sybil G.; Anderson, Peter L.; Seifert, Sharon M.; Kapogiannis, Bill G.; Mulligan, Kathleen // Clinical Infectious Diseases;2/1/2017, Vol. 64 Issue 3, p317 

    Background. We aimed to define the relative importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity. Methods. In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in human immunodeficiency virus (HIV)-uninfected young men who...

  • Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study. Gamage, Deepa G.; Read, Tim R. H.; Bradshaw, Catriona S.; Hocking, Jane S.; Howley, Kerry; Chen, Marcus Y.; Fairley, Christopher K. // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p39 

    Background: We aimed to determine the incidence of Hepatitis C (HCV) infection among HIV-infected men who have sex with men (MSM) attending a Sexual Health Centre. Methods: A retrospective cohort study was carried out among HIV-infected MSM seen at least once between February 2002 and March...

  • Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial). Gallien, Sébastien; Journot, Valérie; Rozenbaum, Willy; Yéni, Patrick; Morlat, Philippe; Poizot-Martin, Isabelle; Reynes, Jacques; Reliquet, Véronique; Leclercq, Pascale; Simon, François; Chêne, Geneviève; Molina, Jean-Michel // Journal of Antimicrobial Chemotherapy (JAC);Jan2011, Vol. 66 Issue 1, p184 

    Background Once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine. Methods The ALIZE ANRS 099 trial enrolled 355 adults with...

  • Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. Thigpen, Michael C.; Kebaabetswe, Poloko M.; Paxton, Lynn A.; Smith, Dawn K.; Rose, Charles E.; Segolodi, Tebogo M.; Henderson, Faith L.; Pathak, Sonal R.; Soud, Fatma A.; Chillag, Kata L.; Mutanhaurwa, Rodreck; Chirwa, Lovemore Ian; Kasonde, Michael; Abebe, Daniel; Buliva, Evans; Gvetadze, Roman J.; Johnson, Sandra; Sukalac, Thom; Thomas, Vasavi T.; Hart, Clyde // New England Journal of Medicine;8/2/2012, Vol. 367 Issue 5, p423 

    Background: Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain. Methods: We randomly assigned HIV-seronegative men and women to...

  • HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. Liegler, Teri; Abdel-Mohsen, Mohamed; Bentley, L. Gordon; Atchison, Robert; Schmidt, Timothy; Javier, Jacqueline; Mehrotra, Megha; Eden, Christopher; Glidden, David V.; McMahan, Vanessa; Anderson, Peter L.; Li, Peilin; Wong, Joseph K.; Buchbinder, Susan; Guanira, Juan V.; Grant, Robert M. // Journal of Infectious Diseases;Oct2014, Vol. 210 Issue 8, p1217 

    Background. The iPrEx study demonstrated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects against HIV acquisition in men who have sex with men and transgender women. Selection for drug resistance could offset PrEP...

  • Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1-Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. DeJesus, Edwin; Rockstroh, Jürgen K.; Lennox, Jeffrey L.; Saag, Michael S.; Lazzarin, Adriano; Zhao, Jing; Wan, Hong; Rodgers, Anthony J.; Walker, Monica L.; Miller, Michael; DiNubile, Mark J.; Nguyen, Bach-Yen; Teppler, Hedy; Leavitt, Randi; Sklar, Peter // HIV Clinical Trials;Jul/Aug2012, Vol. 13 Issue 4, p228 

    We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics